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Introduction
Neuropathic pain represents a particularly frustrating problem for researchers due to its unclear underlying mechanisms and its resistance to routine treatment [1] . In previous decades, our understanding of pain has focused solely on the role of neurons, whereas and the neighboring microglia have been considered simply resident macrophages of the central nervous system (CNS). However, recent studies indicate that microglia can function as key players in the modulation of neuronal network excitability [2] . Furthermore, neuropathic pain pathogenesis depends on both changes in the activity of neuronal systems as well as microglia activation [3] . During the pathogenesis of neuropathic pain, resident microglia become activated [4] , exhibiting up-regulation of the expression of cell surface receptors (including purinergic receptors and CD11b) [5, 6] , enhanced migratory ability [7] and proneurotropic factor (BDNF)) [8, 9 changes can accelerate the development of neuropathic pain.
BDNF, one of the most important neurotrophins, contributes to many aspects of CNS function, including cell differentiation, neuronal survival and migration, dendritic arborization, synaptogenesis and activity-dependent forms of synaptic plasticity [10] . Recently, a growing body of evidence has indicated that BDNF may also represent a key molecule medi- Cruz, CA, USA).
Cell culture
ml penicillin and 100 2 at 37°C.
Western immunoblots
We measured the protein concentration using a BCA protein assay kit (Beyotime Corporation, Nanjing, followed by overnight incubation at 4°C with primary anti-BDNF (1:200; Santa Cruz Corporation, Santa antibodies (1:1000; Santa Cruz Corporation, Santa Cruz, CA, USA). Subsequently, the membranes were
(1:5000; Santa Cruz Corporation,) for 2 h at room temperature. After washing the membranes three times incubated the blots in stripping buffer (Beyotime Corporation, Nangjing, China) for 10 min at 4°C and rewhich was used as the loading control. We determined the immunoreactive band intensity using Quantity Fig. 1a and c) . Next, the cells p<0.01, Fig. 1b and d) . migration. mol/l) were plated in 24-well plates for 24 h.
p<0.01, Fig. 1e , f, and g).
As shown in the supernatant were up-regulated in a dose-and time-dependent manner (p<0.01, Fig. 1 h, l, j, k, l, and m). p<0.01, Fig. 2a , b, c, and d). Fig. 2e , f, g, h, and i). As and synthesis of BDNF (p<0.01, Fig. 2j , k, l, m, n, and o). BDNF; however, when the effects of endogenous BDNF are blocked, microglia activation is down-regulated, leading to the subsequent inhibition of microglial migration and pro- 
p<0.01,

Exogenous BDNF activates microglia, enhancing microglial migration and increasing TNF-release
In this series of experiments, we used exogenous BDNF to further determine whether p<0.01, Fig. 3a, b, c, and d) .
control cells, indicating that exogenous BDNF can enhance microglial migration (p<0.01, Fig. (p<0.01, Fig. 3e and f) . Based on the results of the present
Discussion
). Neuropathic pain is a debilitating chronic pain condition that results from injury to the nervous system and may be caused by cancer, diabetes mellitus, infection, autoimmune diseases, or traumatic injury [16] . BDNF is thought to promote neuronal survival and differenin the developing and adult hippocampus by enhancing synaptic responses to tetanic stimulation [17] . Researchers subsequently began to focus on the effect of BDNF on neuropathic pain. Substantial evidence suggests that BDNF plays a key role in synaptic transmission by potentiating the NMDA receptors present in primary afferents [18] , regulating the pattern 19], and reducing Ca 2+ + 20]. In our previous study, we demonstrated that BDNF could directly activate astrocytes in the spinal dorsal horn in a rat model of neuropathic pain [14] .
BDNF can not only directly activate neurons and astrocytes but can also induce microglia activation. BDNF can regulate the proliferation and survival of cultured microglia [21] . Mizoguchi et al. demonstrated that BDNF could induce the sustained elevation of intracellular Ca 2+ in vitro [22] . Zhou et al. performed several series of experiments to examine the effects of BDNF on microglia in an in vivo rat model and concluded that BDNF can activate spinal microglia, thereby contributing to long-term potentiation and mechanical hypersensitivity of spinal neurons [15] . Notably, in the study by Nakajima and Mizoguchi, pretreatment 22, 23 the method of BDNF administration. In our study, we used BDNF to stimulate microglia directly; however, in the previously discussed experiments, BDNF pretreatment was followed underlying microglial activation. As the dramatic effects of BDNF in the central nervous system are elucidated, the sources of BDNF have received increased researcher attention. BDNF can be synthetized and secreted by neurons, astrocytes and microglia [24, 25] . Microglia-derived BDNF is a critical microglia-neuron signaling molecule that gates aberrant nociceptive processing in the spinal cord [26] .
In recent years, microglia activation has begun to attract greater attention in CNS disease research. When CNS homeostasis is disrupted, microglia adopt an activated state, early-stage microglial activation plays a key role in the maintenance of CNS homeostasis. . However, research focusing on the function of BDNF as an autocrine stimulator of microglia remains lacking. Our recent study indicates that activated microglia can produce additional BDNF, and elevated levels of -sults in prolonged microglial activation, which may contribute to neuropathic pain. Notably, 27 -ment of many pathological conditions. Future experiments will be needed to elucidate the detailed mechanism underlying the relationship between these positive feedback loops and pathological processes such as neuropathic pain. Furthermore, targeting the BDNF pathway may provide a novel therapeutic strategy for pain management.
